Akers Biosciences Inc. (AKER)

[apollo1452]

From the 8-K on 5/21/18:

Item 8.01 Other Events.

"As previously disclosed, the Company has been reviewing the characterization of certain revenue recognition items for the quarter ended March 31, 2018. As this review is continuing and now includes certain transactions in previous quarters, the Company is unable to file its 10-Q for the quarter ended March 31, 2018 today. Following the completion of its review, which cannot be estimated, the Company will file its 10-Q for the quarter ended March 31, 2018 and make a determination as to whether it will need to revise, correct or restate the reports for any previous quarter or fiscal year."

IMHO, this can be interpreted as AKER may have issues with "accounting irregularities". Buyout rumors are meaningless while this plays out.